The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1 : A 10‐year retrospective study-Reference-Cited by-同舟云学术

The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1 : A 10‐year retrospective study

Published:2021-09-04 Issue:11 Volume:96 Page:1461-1471
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Zhou Biqi¹²,Chu Xinran³,Tian Hong¹,Liu Tianhui¹²,Liu Hong¹,Gao Wei³,Chen Suning¹^ORCID,Hu Shaoyan³,Wu Depei¹²,Xu Yang¹²^ORCID

Affiliation:

1. Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases The First Affiliated Hospital of Soochow University Suzhou China

2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China

3. Department of Hematology and Oncology The Children's Hospital of Soochow University Suzhou China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26324

Reference46 articles.

1. Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein

2. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome: a collaborative study of the Groupe Francais de Cytogenetique Hematologique;Groupe Francais de Cytogenetique Hematologique;Blood,1996

3. Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases

4. E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol

5. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Comprehensive summary: the role of PBX1 in development and cancers;Frontiers in Cell and Developmental Biology;2024-07-26

3. Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes;Leukemia Research;2024-06

4. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18

5. The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia;Annals of Hematology;2023-12-27